The DEA completed its administrative hearing on broader marijuana rescheduling from Schedule I to III on July 15, 2026, after which participants filed post-hearing briefs. An administrative law judge will issue a recommended decision before the DEA Administrator determines whether to finalize a rule. Partial rescheduling of FDA-approved products and state-licensed medical marijuana already took effect in April 2026 under a Trump executive order, though that action faces ongoing D.C. Circuit challenges. Trader pricing on near-term full rescheduling reflects the multi-step administrative timeline, expected litigation delays, and the absence of an imminent final rule for general cannabis. Upcoming milestones include the judge’s recommendation and any Administrator action before year-end.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado$812,546 Vol.
31 dez 2026
30 de setembro
2%
31 de dezembro
23%
$812,546 Vol.
30 de setembro
$739 Vol.
2%
31 de dezembro
$202,236 Vol.
23%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA completed its administrative hearing on broader marijuana rescheduling from Schedule I to III on July 15, 2026, after which participants filed post-hearing briefs. An administrative law judge will issue a recommended decision before the DEA Administrator determines whether to finalize a rule. Partial rescheduling of FDA-approved products and state-licensed medical marijuana already took effect in April 2026 under a Trump executive order, though that action faces ongoing D.C. Circuit challenges. Trader pricing on near-term full rescheduling reflects the multi-step administrative timeline, expected litigation delays, and the absence of an imminent final rule for general cannabis. Upcoming milestones include the judge’s recommendation and any Administrator action before year-end.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercado Aberto: Feb 7, 2026, 5:04 PM ET
Volume
$812,546Data de Término
1 jan 2027Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The DEA completed its administrative hearing on broader marijuana rescheduling from Schedule I to III on July 15, 2026, after which participants filed post-hearing briefs. An administrative law judge will issue a recommended decision before the DEA Administrator determines whether to finalize a rule. Partial rescheduling of FDA-approved products and state-licensed medical marijuana already took effect in April 2026 under a Trump executive order, though that action faces ongoing D.C. Circuit challenges. Trader pricing on near-term full rescheduling reflects the multi-step administrative timeline, expected litigation delays, and the absence of an imminent final rule for general cannabis. Upcoming milestones include the judge’s recommendation and any Administrator action before year-end.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$812,546Data de Término
1 jan 2027Mercado Aberto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The DEA completed its administrative hearing on broader marijuana rescheduling from Schedule I to III on July 15, 2026, after which participants filed post-hearing briefs. An administrative law judge will issue a recommended decision before the DEA Administrator determines whether to finalize a rule. Partial rescheduling of FDA-approved products and state-licensed medical marijuana already took effect in April 2026 under a Trump executive order, though that action faces ongoing D.C. Circuit challenges. Trader pricing on near-term full rescheduling reflects the multi-step administrative timeline, expected litigation delays, and the absence of an imminent final rule for general cannabis. Upcoming milestones include the judge’s recommendation and any Administrator action before year-end.
Resumo experimental gerado por IA com dados do Polymarket. Isto não é aconselhamento de trading e não tem qualquer papel na resolução deste mercado. · Atualizado
Cuidado com os links externos.
Cuidado com os links externos.
Frequently Asked Questions